PTEN (Tumor Suppressor Protein) polyclonal, anti-human

Description:
Recognizes a protein of 55kDa, which is identified as PTEN. PTEN is one of the most commonly lost tumor suppressors in human cancer; in fact, up to 70% of men with prostate cancer are estimated to have lost a copy of the PTEN gene at the time of diagnosis. During tumor development, mutations and deletions of PTEN occur that inactivate its enzymatic activity leading to increased cell proliferation and reduced cell death. Frequent genetic inactivation of PTEN occurs in glioblastoma, endometrial cancer, and prostate cancer; and reduced expression is found in many other tumor types such as lung and breast cancer. In breast and prostate cancer, loss of PTEN expression has been shown to correlate positively with advanced stage. Furthermore, PTEN mutation also causes a variety of inherited predispositions to cancer.

Synonyms:
Bannayan Zonana syndrome (BZS), DEC, GLM2, ITGA 2, MHAM, Multiple hamartoma (Cowden syndrome), Mutated in Mutiple Advanced Cancers 1 (MMAC1), Phosphatase and tensin like protein, Phosphatidylinositol 345 trisphosphate 3 phosphatase, Platelet antigen BR, PTEN1, Tensin homolog, TEP1, VLA 2 Receptor Alpha Subunit

Isotype: Rabbit Ig

Immunogen:
Recombinant full-length human PTEN protein

Form: Purified, in 10mM PBS with 0.05% BSA & 0.05% azide. Also available WITHOUT BSA & azide at 1.0mg/ml.

Reactivity: human. Others not known.

Applications: Flow Cytometry (0.5-1ug/million cells)
Immunofluorescence (1-2ug/ml)
Western Blotting (0.5-1ug/ml)
Optimal dilution for a specific application should be determined.

Positive Control:
HeLa cells. Prostate Carcinoma.

Molecular Weight:
55kDa

Concentration:
0.2mg/ml

Storage: Can be stored at +4C. For long term storage, aliquot and store at -20C. Avoid repeated freezing and thawing cycles.